Physician profile
Anne Le
NPI 1174091326
$10,802.07
in general payments reported to CMS, 2019-2025
40 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,840 · 2022: $2,969 · 2023: $2,332 · 2024: $1,040 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889 · Education: $99.99 · Travel and Lodging: $4.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.37 |
| Education | $99.99 |
| Travel and Lodging | $4.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,583.75 | 2021-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $1,170.43 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $976.46 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $928.67 | 2021-2025 | |
| Lilly USA, LLC | $910.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $890.90 | 2021-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.64 | 2021-2024 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $548.90 | 2021-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $510.42 | 2021-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $332.05 | 2021-2024 | Yupelri |
| Pfizer INC. | $293.90 | 2021-2025 | |
| Amarin Pharma, INC. | $216.41 | 2021-2022 | |
| Redhill Biopharma INC. | $194.35 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $160.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.26 | 2023-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.